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A 25-year-old black male with AIDS, who had a CD4 count of 9
cells/ml and a viral load of 31 000 copies/ml, presented in
October 2006 with a 3-month history of weakness in both
lower limbs. He was unable to walk unaided, and described
‘pins and needles’ in his legs and decreased sensation up to
approximately thoracic dermatomal level 12. He described a
dull lumbo-sacral backache with no sphincter dysfunction.
He had a history of treatment for pulmonary tuberculosis
in 2000.
On examination, he was cachectic with generalized
lymphadenopathy and oral thrush. He was apyrexial and
normotensive with a pulse rate of 86 beats/min. He was
lucid and did not display any neck stiffness. Examination of
the cranial nerves and upper limbs was normal apart from
proprioceptive loss in the upper limbs. The tone in his
lower limbs was increased and the power in his lower limbs
was Medical Research Council scale (MRC) grade 4. The
knee reflexes were brisk but the ankle reflexes were
diminished. The plantar responses were extensor bilater-
ally. He had global joint position sense loss and had a
thoracic dermatomal sensory level of 9 to pinprick and
light touch.
In view of his marked immunosuppression and clinical
presentation, the diagnosis of vacuolar myelopathy was sus-
pected. Further blood investigations andmagnetic resonance
imaging (MRI) was done to confirm the diagnosis and exclude
other causes of HIV-associated myelopathy, from opportunis-
tic infections to neoplasms.
Blood investigations showed normal vitamin B12 and folate
levels, a normocytic normochromic anemia, and negative
screens for toxoplasmosis and syphilis. Cerebrospinal fluid
examination showed no cells and normal chemistry. MRI
of the entire cord revealed no intra- or extradural masses.
However there was a prominent T2 hyperintensity of the
posterior columns extending from the upper cervical to lower
thoracic cord. No contrast enhancement was noted. The
features were consistent with vacuolar myelopathy (see
Figures 1 and 2).
MRI features of vacuolar myelopathy are well described
and on axial views appear as high intensity lesions involving
the posterior columns. A peripheral axonal neuropathy is
a common accompaniment of vacuolar myelopathy and1201-9712/$32.00 # 2007 International Society for Infectious Diseases.probably reflects the degree of immunosuppression in
patients, rather than sharing a common pathophysiology.
Vacuolar myelopathy is a common form of spinal cord
disease in HIV positive patients.1 Petito et al. performed
an autopsy-based study, which revealed that 20/89 (22%)
patients had vacuolar myelopathy.1,2 An even higher preva-
lence of 46.5% was reported by Dal Pan et al. Despite this high
frequency, only 26.8% of patients with autopsy-proven vacuo-
lar myelopathy had signs and symptoms.3 Vacuolar myelo-
pathy is often accompanied by other neurological disorders
associated with advanced AIDS, and this may explain why it is
often clinically under-recognized.1
Pathologically, vacuolar myelopathy is characterized by
intralamellar vacuolation in the spinal white matter through-
out the lateral and posterior columns of the thoracic and,
occasionally, the cervical segments of the spinal cord.1,4,5
There are a few theories concerning the pathophysiology of
vacuolar myelopathy. These include: infiltration by neuro-
toxic cytokines, direct HIV infection of astrocytes and neu-
rons, neurotoxic HIV proteins, and the impaired ability to
utilize vitamin B12 as a source of methionine in transmethy-
lation metabolism for myelin maintenance in the spinal
cord.6
Vacuolar myelopathy is a diagnosis of exclusion, and other
spinal cord diseases (both infectious and non-infectious
causes), which may mimic this condition, must be ruled
out. Vitamin B12 deficiency occurs in 13—50% of HIV infected
individuals.7—9 Subacute combined degeneration of the
spinal cord in the presence of normal vitamin B12 levels
(and megaloblastic anemia) has been described.10 This
patient had no predisposing factors to vitamin B12 deficiency
except for HIV infection, and in the absence of vitamin B12
replenishment the myelopathy improved. This supports a
diagnosis of vacuolar myelopathy with response to highly
active antiretroviral therapy (HAART) rather than B12 defi-
ciency-associated subacute combined degeneration of the
spinal cord.
The manifestation of vacuolar myelopathy is varied and
often presents as a painless spastic paraparesis that is slowly
progressive, with a sensory ataxia.5 There may be an asso-
ciated sphincter and erectile dysfunction. Overlapping per-
ipheral neuropathy may provide a diagnostic challenge.1
Hyperreflexia at the knees is a common finding with reduced
ankle reflexes.1 Backpain is not commonandadiscrete sensory
level if present suggests an alternative cause of myelopathy.6
In our patient however, in the absence of an alternative causePublished by Elsevier Ltd. All rights reserved.
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Figure 2 T2 axial spine: pre-treatment at T10/11. Hyperin-
tense posterior columns demonstrated. Note: trefoil appearance
of hyperintensity.
Figure 4 T2 axial spine: post-treatment. Significant reduction
in T2 hyperintensity of posterior column.
Figure 3 T2 sagittal thoracic spine: post-treatment.
Figure 1 T2 sagittal thoracic spine: pre-treatment.we feel his low backache and crisp sensory level had to be
associated with his diagnosis of vacuolar myelopathy.
The treatment of vacuolar myelopathy is uncertain; it is
mainly supportive and HAART is believed to improve the
prognosis.4 In addition there have been anecdotal case
reports of improvement on HAART.4,6 This patient was started
on HAART (regimen 1a: stavudine, lamivudine, and efavirenz)
shortly after discharge. Seven months later the patient has
made a remarkable recovery. Whilst his CD4 count increase is
modest, just 87 cells/ml, his viral load is <25 copies/ml, his
weight has increased by 15 kg, and he now walks unaided. In
addition, his neurological examination has revealed normal
joint position sense in the upper limbs andmild impairment in
the lower limbs. The glove and stocking sensory impairment
and the peripheral neuropathy persist and are being treated
symptomatically.
Repeat MRI of the spine following 7 months of HAART has
revealed significant reduction of the T2 hyperintensity of the
posterior columns noted on the pre-treatment films (see
Figures 3 and 4).
This case report supports other anecdotal reports of the
benefit of HAART in vacuolar myelopathy and highlights the
need for case—controled studies to investigate qualitatively
and quantitatively the role of HAART in the management of
vacuolar myelopathy.
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Acute liver failure is a condition in which there is rapid
deterioration of liver function, resulting in hepatic encepha-
lopathy and/or coagulopathy.1 In Latin America, complicated
forms of certain tropical infections such as Plasmodium
falciparum malaria, leptospirosis, rickettsial fever, typhoid
fever, viral hepatitis, and rarely dengue, may present as
acute liver failure. Early identification of these infections
is important in reducing morbidity and mortality.2
A 31-year-old previously healthy female presented at our
clinic with a 3-day history of fever, myalgia, bilirubinuria,
arthralgia, and altered mental status. She denied having any
previous history of dengue or malaria. Physical examination
disclosed a diffuse maculopapular rash, asterixis, and jaun-
dice. Ten days prior to her admission she had traveled to
Tolima, Colombia, a hyperendemic area for dengue infection
where an ongoing outbreak due to DEN-2 (dengue virus
serotype 2) was taking place. Laboratory investigations on
admission showed a normal white blood cell (WBC) count and
mild thrombocytopenia; blood chemistries demonstrated a
bilirubin of 8.1 mg/dl, ASTof 2876 UI/l, and ALTof 2120 UI/l.
Her international normalized ratio (INR) was 4.47 with a
prolonged prothrombin time (PT) and a prolonged partial
thromboplastin time (PTT). Thick and thin smears for malaria
and blood cultures were negative. Diagnostic testing for
hepatitis A (IgM), hepatitis B (HBsAg, HBV DNA PCR), hepatitis
C (IgG, HCV RNA PCR), hepatitis E (IgM, IgG), yellow fever
(RNA PCR), Rickettsia spp (IgM/IgG), Epstein—Barr virus,
cytomegalovirus, parvovirus B19 (IgM, IgG), HIV (RNA PCR),
and leptospirosis (ELISA IgM and MAT) were all negative. Her
dengue IgM titers were positive at high titers. There was no
evidence of dengue hemorrhagic fever. A diagnosis of acute
liver failure due to dengue was then made. Despite suppor-
tive efforts, our patient progressed to multiorgan failure and
subsequently died.The clinical spectrum of dengue infections ranges from
asymptomatic infection, to dengue fever (DF), to dengue
hemorrhagic fever (DHF) and dengue shock syndrome
(DHS).2,3 However, sometimes dengue may manifest with
atypical clinical presentations such as acute liver failure.
Indeed, up to 90% of patients with DF may develop mild to
moderateelevationof liver transaminaseswithhigher levelsof
AST.4,5 Liver involvement in DF and DHF has been described in
Asia and the Pacific Islands, and more recently in the Amer-
icas.4—6 However, acute liver failure has rarely been reported
in the setting of DF, andmost of these reports have occurred in
children with DHF and have frequently been associated with
DEN-3 (dengue virus serotype 3) infection.4—6
Dengue virus liver injury may occur due to its ability to
replicate in liver cells leading to hepatocellular injury with
development of Councilman bodies.7,8 In fact, in situ detec-
tion of DNA fragmentation and apoptotic hepatocytes in
association with dengue virus-infected hepatocytes has sug-
gested that hepatocytes are important sites of viral replica-
tion and that dengue virus induces apoptosis in vivo.7
Our case demonstrates that in addition to classic DF and
DHF, testing for dengue should also be pursued among tra-
velers returning from tropical areas endemic for dengue
presenting with acute liver failure.
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